Medikamentöse Therapie bei Frauen - Was gilt es zu beachten?

被引：0
作者：
Ravens U. [1 ]
机构：
[1] Institut für Pharmakologie und Toxikologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74
来源：
Clinical Research in Cardiology Supplements | 2013年 / 8卷 / Suppl 1期
关键词：
Drug therapy; Pharmacodynamics; Pharmacokinetics; Risk for adverse drug reactions (ADR); Sex differences;
D O I：
10.1007/s11789-013-0055-0
中图分类号：
学科分类号：
摘要：
Women and men exhibit different reactions to drugs. Sex-based pharmacokinetic differences relate mainly to the rate of biotransformation and to the distribution of drugs. Women have a significantly larger risk for adverse drug reactions than men. Sex-dependence of drug therapy is a multifactorial problem clearly demonstrating the necessity for specific investigations into the biological differences between women and men concerning drug therapy. Known differences should be included into guide line recommendations. © 2013 Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：32 / 37
页数：5
相关论文
共 46 条
[1]  
Harris, D.J., Douglas, P.S., Enrollment of women in cardiovascular clinical trials funded by the national heart, lung, and blood institute (2000) N Engl J Med, 343, pp. 475-480
[2]  
Schmucker, D.L., Vesell, E.S., Underrepresentation of women in clinical drug trials (1993) Clin Pharmacol Ther, 54, pp. 11-15
[3]  
Kim, A.M., Tingen, C.M., Woodruff, T.K., Sex bias in trials and treatment must end (2010) Nature, 465, pp. 688-689
[4]  
Lee, I.M., Cook, N.R., Gaziano, J.M., Gordon, D., Ridker, P.M., Manson, J.E., Hennekens, C.H., Buring, J.E., Vitamin E in the primary prevention of cardiovascular disease and cancer: The women's health study: A randomized controlled trial (2005) Jama, 294, pp. 56-65
[5]  
Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Ockene, J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial (2002) Jama, 288, pp. 321-333
[6]  
Evans, R.S., Lloyd, J.F., Stoddard, G.J., Nebeker, J.R., Samore, M.H., Risk factors for adverse drug events: A 10-year analysis (2005) Ann Pharmacother, 39, pp. 1161-1168
[7]  
Rademaker, M., Do women have more adverse drug reactions? (2001) Am J Clin Dermatol, 2, pp. 349-351
[8]  
Anderson, G.D., Sex and racial differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics (2005) J Womens Health (Larchmt), 14, pp. 19-29
[9]  
Schwartz, J.B., The influence of sex on pharmacokinetics (2003) Clin Pharmacokinet, 42, pp. 107-121
[10]  
Soldin, O.P., Mattison, D.R., Sex differences in pharmacokinetics and pharmacodynamics (2009) Clin Pharmacokinet, 48, pp. 143-157
12345